RSPR Pharma is a Swedish pharmaceutical company developing an oral anti-asthmatic drug providing mast cell control by inhibiting both induced and basal release of asthma mediators.
Asthma is an inflammatory condition affecting some 300 million people worldwide and despite gold standard therapy (inhaled corticosteroids, which do not target mast cells) only 50% of patients reach asthma control. The RSPR Pharma compound is currently in clinical development and is intended for patients not controlled by corticosteroids.
Location: Sweden, Uppsala
Employees: 11-50
Investors 2
| Date | Name | Website |
| 19.02.2021 | HealthCap | healthcap.... |
| - | Forbion | forbion.co... |
Mentions in press and media 2
| Date | Title | Description | Source |
| - | RSPR Pharma initiates Phase II clinical trial of oral mast c... | Stockholm 2015-12-08 RSPR Pharma AB today announced the initiation of a phase II clinical proof of ... | healthcap.... |
| - | RSPR Pharma hires Paul de Potocki as Chief Business Officer | Stockholm 2016-08-23 RSPR Pharma AB today announced that Paul de Potocki will join the company as C... | healthcap.... |